MPD: Phenotype measures mapped to MA:0000168, brain

An error occurred on this page.
These results could be incomplete or invalid. Staff have been notified.

Phenotype measures directly associated with ontology term
MA:0000168 'brain'

This list only includes measures mapped to MA:0000168 directly. Measures mapped to its ontology descendants are not included. Alternatively, you can show measures mapped to MA:0000168 AND its descendants.

MA:0000188 corpus callosum
MA:0000191 hippocampus
MA:0000198 cerebellum
MA:0000817 brain subventricular zone
MA:0000941 temporal cortex
MA:0000946 dentate gyrus granule cell layer
MA:0002723 hippocampal commissure

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Bopp1:4	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in brain relative to all organs tested [%] luciferase_brain 36404	inbred	28	both	8-12wks	N=2	2010

Brich1:1	Brich1	metabolite quantification	(none)	tau phosphorylation level [score] level 12801	QTL population		f	3wks	N=51	2003

Brinkmeyer1:33	Brinkmeyer1	RNA expression profiling	Theiler's murine encephalomyelitis virus	TMEV transcript abundance (normalized), post infection TMEV 64433 day 7 day 28	CC	4	both	4wks	N=1	2017

Chesler3:91	Chesler3	organ weights	(none)	brain weight [g] brain_wt 43591	CC pre w/par	181	both	7-15wks	N=1	2011

Crabbe2:1	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, 30 min post-injection [ng/g] brain_DZ 15501 8 mg/kg 16 mg/kg	inbred	15	m	6-7wks	N=8	1998

Crabbe2:3	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, <5 min post-injection, after rotarod [ng/g] brain_DZ20 15503 trial block1 trial block2	inbred	15	m	6-7wks	N=13	1998

Crusio1:45	Crusio1	organ weights	(none)	brain weight [g] brain_wt 62045	BXD w/par	55	both	12-16wks	N=8	2018

Crusio1:46	Crusio1	organ weights	(none)	brain weight as percentage of total body weight [%] brain_wt_pct 62046	BXD w/par	55	both	12-16wks	N=8	2018

Crusio1:48	Crusio1	histopathology	(none)	total hippocampus size (arbitrary units) hippocampus 62048 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:50	Crusio1	histopathology	(none)	size of intra- and infrapyramidal mossy fibers (arbitrary units) iipmf 62050 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:52	Crusio1	histopathology	(none)	percentage of hippocampus that is Intra- and infrapyramidal mossy fibers [%] iipmf_pct 62052 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:55	Crusio1	histopathology	(none)	size of hilus (arbitrary units) hilus 62055 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:57	Crusio1	histopathology	(none)	percentage of hippocampus that is hilus [%] hilus_pct 62057 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:60	Crusio1	histopathology	(none)	size of suprapyramidal mossy fibers (arbitrary units) supra 62060 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:62	Crusio1	histopathology	(none)	percentage of hippocampus that is suprapyramidal mossy fibers [%] supra_pct 62062 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:65	Crusio1	histopathology	(none)	size of stratum pyramidale (arbitrary units) pyr 62065 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:67	Crusio1	histopathology	(none)	percentage of hippocampus that is stratum pyramidale [%] pyr_pct 62067 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:70	Crusio1	histopathology	(none)	size of stratum oriens (arbitrary units) oriens 62070 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:72	Crusio1	histopathology	(none)	percentage of hippocampus that is stratum oriens [%] oriens_pct 62072 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:75	Crusio1	histopathology	(none)	size of stratum radiatum (arbitrary units) rad 62075 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:77	Crusio1	histopathology	(none)	percentage of hippocampus that is stratum radiatum [%] rad_pct 62077 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:80	Crusio1	histopathology	(none)	size of stratum lacunosum-moleculare (arbitrary units) lacun 62080 left right	BXD w/par	55	both	12-16wks	N=4	2018

Crusio1:82	Crusio1	histopathology	(none)	percentage of hippocampus that is stratum lacunosum-moleculare [%] lacun_pct 62082 left right mean	BXD w/par	55	both	12-16wks	N=4	2018

Davidson1:1	Davidson1	health assessment	(none)	0=exencephaly, 1=normal [score] Exencephaly 19201	QTL population		both	embryo	N=94	2007

Davidson1:2	Davidson1	health assessment	(none)	1=exencephaly, 0=normal [score] Exen2 19202	QTL population		both	embryo	N=94	2007

Frankel1:1	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for minimal clonic seizure, frontal stimulation (at BH) [mA] E_MC_BH_FS 5601	inbred	4	m	6-11wks	N=35	2000

Frankel1:2	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀), transcorneal stimulation (at BH) [mA] E_MC_BH_TC 5602	inbred	16	both	6-11wks	N=33	2000

Frankel1:3	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀), transcorneal stimulation (at SL) [mA] E_MC_SL_TC 5603	inbred	8	both	6-11wks	N=29	2000

Frankel1:4	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, frontal stimulation (at BH) [mA] E_MT_BH_FS 5604	inbred	4	m	6-11wks	N=44	2000

Frankel1:5	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, transcorneal stimulation (at BH) [mA] E_MT_BH_TC 5605	inbred	16	both	6-11wks	N=38	2000

Frankel1:6	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for maximal tonic hindlimb extension seizure, transcorneal stimulation (at SL) [mA] E_MT_SL_TC 5606	inbred	8	both	6-11wks	N=29	2000

Frankel1:7	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, frontal stimulation (at BH) [mA] E_PS_BH_FS 5607	inbred	4	m	6-11wks	N=41	2000

Frankel1:8	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, transcorneal stimulation (at BH) [mA] E_PS_BH_TC 5608	inbred	14	both	6-11wks	N=41	2000

Frankel1:9	Frankel1	electroconvulsion test	(none)	median critical current (CC₅₀) for psychomotor seizure, transcorneal stimulation (at SL) [mA] E_PS_SL_TC 5609	inbred	7	both	6-11wks	N=39	2000

Frankel1:10	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against minimal clonic seizures (CC₉₇), transcorneal stimulation (at BH) [mg/kg] L_MC_BH_TC 5610	inbred	3	m	6-11wks	N=63	2000

Frankel1:12	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against minimal clonic seizures (CC₉₇), transcorneal stimulation (at SL) [mg/kg] L_MC_SL_TC 5612	inbred	3	m	6-11wks	N=51	2000

Frankel1:13	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against maximal tonic hindlimb extension seizure (CC₉₇), transcorneal stimulation (at BH) [mg/kg] L_MT_BH_TC 5613	inbred	3	m	6-11wks	N=52	2000

Frankel1:14	Frankel1	electroconvulsion test	lamotrigine	median effective dose (ED₅₀) against maximal tonic hindlimb extension seizure (CC₉₇), transcorneal stimulation (at SL) [mg/kg] L_MT_SL_TC 5614	inbred	3	m	6-11wks	N=45	2000

Gould1:8	Gould1	drug and metabolite quantification	lithium	brain lithium concentration [mmol/L] brain_lithium 37408 lithium dose [mg/kg]: 200 300 400	inbred	11	m	7-8wks	N=8	2011

Graham1:29	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD4+ in brain, post infection [%] CD4_brain 63329 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:37	Graham1	immune cell quantification	West Nile virus	percentage of CD4+ T cells that are Foxp3+ in the brain, post infection [%] Treg_brain 63337 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:45	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD8+ in brain, post infection [%] CD8_brain 63345 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:53	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are NS4b+ in brain, post infection [%] NS4b_brain 63353 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:65	Graham1	RNA expression profiling	West Nile virus	virus in brain, fold change compared to matched control, post infection WNV_brain 63365 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:76	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in brain, fold change compared to matched control, post infection Ifnb1_brain 63376 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:87	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in brain, fold change compared to matched control, post infection Ifit1_brain 63387 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Jaxpheno2:1	Jaxpheno2	organ weights	(none)	brain weight [g] brain 22701 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno2:3	Jaxpheno2	organ weights	(none)	brain weight as percentage of body weight [%] pct_brain 22703 age 8wks age 16wks	inbred	11	both		N=8	2006

Marchuk1:1	Marchuk1	histopathology	(none)	infarct volume following surgically-induced focal cerebral ischemia [mm³] infarct_vol 45001	inbred	16	both	11-13wks	N=4	2009

Molenhuis1:8	Molenhuis1	organ weights	(none)	brain weight [g] brain_wt 110075	CC	52	m	7-20wks	N=5	2018

Mooney1:1	Mooney1	protein activity assessment	(none)	cerebellum acetylcholinesterase activity [mU/mL] CB_AChE 110424	inbred	20	m	8-12wks	N=6	2019

Mooney1:2	Mooney1	protein activity assessment	(none)	dorsal hippocampus acetylcholinesterase activity [mU/mL] DH_AChE 110425	inbred	20	m	8-12wks	N=6	2019

Mooney1:3	Mooney1	protein activity assessment	(none)	ventral hippocampus acetylcholinesterase activity [mU/mL] VH_AChE 110426	inbred	20	m	8-12wks	N=6	2019

Neuner1:9	Neuner1	biomarker quantification	(none)	temporal cortex amyloid level (ng/mg total protein) [ng/mg] amyloid 65909 6 mo 14 mo	F1 AD-BXD	23	both	23-57wks	N=2	2019

Poon1:1	Poon1	histopathology	(none)	BrdU+ cells of rostral migratory stream [n/mm] RMS 47501 3mo 12mo 18mo	inbred	9	both		N=3	2013

Reed2:31	Reed2	organ weights	(none)	brain weight [g] brain_wt 53131	B6.129 and 129.B6 consomic w/par	9	both	26wks	N=17	2015

Rhodes1:3	Rhodes1	microscopy	exercise	hippocampus: volume of dentate gyrus [mm³] DG_vol 34603 control with running wheel	inbred	12	both	15wks	N=4	2010

Rhodes1:5	Rhodes1	microscopy	exercise	hippocampus: number of new neurons in dentate gyrus [n] DG_neurons 34605 control with running wheel	inbred	12	both	15wks	N=4	2010

Rhodes1:7	Rhodes1	microscopy	exercise	hippocampus: density of new neurons in dentate gyrus [n/mm³] DG_density 34607 control with running wheel	inbred	12	both	15wks	N=4	2010

Richfield1:22	Richfield1	neurotransmitter quantification	(none)	dopamine (DA), ng per mg total protein [ratio] DA 14522	inbred	15	m	7-9wks	N=10	2003

Richfield1:23	Richfield1	neurotransmitter quantification	(none)	3,4-dihydroxyphenylacetic acid (DOPAC), ng per mg total protein [ratio] DOPAC 14523	inbred	15	m	7-9wks	N=10	2003

Richfield1:24	Richfield1	neurotransmitter quantification	(none)	4-hydroxy-3-methoxyphenylacetic acid (HVA), ng per mg total protein [ratio] HVA 14524	inbred	15	m	7-9wks	N=10	2003

Richfield1:25	Richfield1	neurotransmitter quantification	(none)	serotonin (5HT), ng per mg total protein [ratio] 5HT 14525	inbred	15	m	7-9wks	N=10	2003

Richfield1:26	Richfield1	neurotransmitter quantification	(none)	dopamine turnover ([DOPAC]/[DA]) [ratio] DA_turnover1 14526	inbred	15	m	7-9wks	N=10	2003

Richfield1:27	Richfield1	neurotransmitter quantification	(none)	dopamine turnover ([DOPAC] + [HVA]/[DA]) [ratio] DA_turnover2 14527	inbred	15	m	7-9wks	N=10	2003

Rosen1:1	Rosen1	histopathology	(none)	corpus callosum area [mm²] corpus_callosum 47801	BXD w/par	78	both	varies	N=2	2012

Rosen1:2	Rosen1	histopathology	(none)	corpus callosum area, adjusted [mm²] corpus_callosum_adj 47802	BXD w/par	78	both	varies	N=2	2012

Schalkwyk2:1	Schalkwyk2	RNA expression profiling	(none)	miR-15b, hippocampal microRNA expression, relative miR15b 48101	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:2	Schalkwyk2	RNA expression profiling	(none)	miR-31, hippocampal microRNA expression, relative miR31 48102	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:3	Schalkwyk2	RNA expression profiling	(none)	miR-34c, hippocampal microRNA expression, relative miR34c 48103	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:4	Schalkwyk2	RNA expression profiling	(none)	miR-212, hippocampal microRNA expression, relative miR212 48104	BXD w/par	26	m	15-16wks	N=4	2012

Schalkwyk2:5	Schalkwyk2	RNA expression profiling	(none)	miR-301a, hippocampal microRNA expression, relative miR301a 48105	BXD w/par	26	m	15-16wks	N=4	2012

Schauwecker1:1	Schauwecker1	health assessment	pilocarpine	pilocarpine dose required to induce status epilepticus, mg/kg body weight [mg/kg] ED100 47701	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:2	Schauwecker1	health assessment	pilocarpine	latency to onset of stage 4 status epilepticus seizures [min] latency 47702	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:3	Schauwecker1	health assessment	pilocarpine	duration of stage 4 status epilepticus seizures [min] duration 47703	inbred	8	m	8-10wks	N=4	2012

Schauwecker1:4	Schauwecker1	health assessment	pilocarpine	status epilepticus seizure mortality (0=died; 1=survived) [designation] survival 47704	inbred	11	m	8-10wks	N=18	2012

Tsaih1:2	Tsaih1	organ weights	(none)	mean of the brain weight in each line mean_brain 18102	QTL population		both		N=106	2005

Wahlsten1:4	Wahlsten1	organ weights	(none)	brain weight, after fixation and trimming [g] brain_wt 10804 weight as percent of body weight	inbred	21	both	12wks	N=10	2003

Wahlsten1:6	Wahlsten1	histopathology	(none)	length of corpus callosum at mid-sagittal plane [mm] cc_length 10806	inbred	21	both	12wks	N=10	2003

Wahlsten1:7	Wahlsten1	histopathology	(none)	length of hippocampal commissure at mid-sagittal plane [mm] hc_length 10807	inbred	21	both	12wks	N=10	2003

Wahlsten1:8	Wahlsten1	histopathology	(none)	length of anterior commissure at mid-sagittal plane [mm] ac_length 10808	inbred	21	both	12wks	N=10	2003

Wahlsten1:9	Wahlsten1	histopathology	(none)	cross-sectional area of corpus callosum at midplane [mm²] cc_area 10809	inbred	21	both	12wks	N=10	2003

Wahlsten1:10	Wahlsten1	histopathology	(none)	cross-sectional area of hippocampal commissure at midplane [mm²] hc_area 10810	inbred	21	both	12wks	N=10	2003

Wahlsten1:11	Wahlsten1	histopathology	(none)	cross-sectional area of anterior commissure at midplane [mm²] ac_area 10811	inbred	21	both	12wks	N=10	2003

Wahlsten1:12	Wahlsten1	histopathology	(none)	corpus callosum index (0=absent, 1=normal, <0.65 is abnormal) [score] cc_index 10812	inbred	21	both	12wks	N=10	2003

Wahlsten1:13	Wahlsten1	histopathology	(none)	hippocampal commissure index (0=absent, 1=normal, <0.5 is abnormal) [score] hc_index 10813	inbred	21	both	12wks	N=10	2003

Wahlsten1:14	Wahlsten1	histopathology	(none)	anterior commissure index (0=absent, 1=normal, <.60 is abnormal) [score] ac_index 10814	inbred	21	both	12wks	N=10	2003

Wiltshire3:1	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:4	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:7	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:10	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:13	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:16	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:19	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:22	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAD1 (GAD67), relative fluorescence intensity GAD1 38122 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:25	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAL, relative fluorescence intensity GAL 38125 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:28	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:31	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:34	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:37	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GLO1, relative fluorescence intensity GLO1 38137 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:40	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GNB1, relative fluorescence intensity GNB1 38140 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:43	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GRIN1 (NMDA1), relative fluorescence intensity GRIN1 38143 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:46	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSK3B, relative fluorescence intensity GSK3B 38146 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:49	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:52	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex HDAC5, relative fluorescence intensity HDAC5 38152 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:55	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:58	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NPY, relative fluorescence intensity NPY 38158 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:61	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:64	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:67	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PPP1R1B, relative fluorescence intensity PPP1R1B 38167 control fluoxetine	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:70	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:73	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex S100B, relative fluorescence intensity S100B 38173 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:76	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:79	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:82	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:85	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:88	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:91	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

An error occurred on this page.These results could be incomplete or invalid. Staff have been notified.

Filter Table Results

An error occurred on this page.
These results could be incomplete or invalid. Staff have been notified.